Trial Profile
A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Paclitaxel
- Indications Prostate cancer
- Focus Adverse reactions
- 10 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Jul 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
- 24 Jul 2014 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.